Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0073 | 0.9254 | 1 |
Mycobacterium tuberculosis | Inositol-1-monophosphatase SuhB | 0.0034 | 0.2658 | 0.5 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0047 | 0.4858 | 0.525 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0061 | 0.7332 | 1 |
Mycobacterium leprae | possible inositol monophosphatase SubH (IMPase) (inositol-1-phosphatase) (I-1-Pase ). | 0.0034 | 0.2658 | 0.5 |
Loa Loa (eye worm) | inositol-1 | 0.0038 | 0.333 | 0.3598 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0023 | 0.0851 | 0.0739 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0023 | 0.0851 | 0.0679 |
Mycobacterium ulcerans | extragenic suppressor protein SuhB | 0.0038 | 0.333 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0037 | 0.3186 | 0.4076 |
Brugia malayi | Bromodomain containing protein | 0.0039 | 0.3599 | 0.2673 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0047 | 0.4858 | 0.4115 |
Schistosoma mansoni | inositol monophosphatase | 0.0038 | 0.333 | 0.3931 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0023 | 0.0851 | 0.0739 |
Echinococcus granulosus | inositol monophosphatase 1 | 0.0038 | 0.333 | 0.4282 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0047 | 0.4858 | 0.5936 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0038 | 0.333 | 0.5 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0021 | 0.0518 | 0.0559 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0037 | 0.3186 | 0.4076 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0038 | 0.333 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0047 | 0.4858 | 0.6466 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0038 | 0.333 | 0.5 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0038 | 0.333 | 0.5 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0038 | 0.333 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.3611 | 0.3902 |
Brugia malayi | Inositol-1 | 0.0038 | 0.333 | 0.2365 |
Toxoplasma gondii | inositol(myo)-1(or 4)-monophosphatase 2, putative | 0.0038 | 0.333 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0047 | 0.4858 | 0.6466 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.4024 | 0.4348 |
Schistosoma mansoni | bromodomain containing protein | 0.0065 | 0.7956 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0044 | 0.4357 | 0.4709 |
Wolbachia endosymbiont of Brugia malayi | fructose-1,6-bisphosphatase | 0.0038 | 0.333 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0061 | 0.7332 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0047 | 0.4858 | 0.5936 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0047 | 0.4858 | 0.5936 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0038 | 0.333 | 0.5 |
Echinococcus multilocularis | inositol monophosphatase 1 | 0.0038 | 0.333 | 0.4282 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0047 | 0.4858 | 0.6466 |
Trichomonas vaginalis | inositol monophosphatase, putative | 0.0038 | 0.333 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0021 | 0.0518 | 0.0242 |
Schistosoma mansoni | inositol monophosphatase | 0.0038 | 0.333 | 0.3931 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0047 | 0.4858 | 0.6466 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0038 | 0.333 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.